Li, Xingya
Capital Medical University · Beijing Tian Tan Hospital · First Affiliated Hospital of Zhengzhou University
2 papers on CoChatORCID 0000-0001-9121-6613
Most cited papers
- Verified
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 22
- Verified
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
Li, J., Wang, Z., Huang, J., Ba, Y., Cao, B., Luo, S., Li, W., Bai, C., Song, Z., Xiong, J., et al. (2026) · The Lancet Gastroenterology & Hepatology
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 3
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free